ARTICLE | Top Story

Omeros soars on Phase II OMS721 data

August 19, 2015 12:51 AM UTC

Omeros Corp. (NASDAQ:OMER) jumped $10.48 (72%) to $25.03 on Tuesday after reporting data from four patients in an ongoing Phase II dose-escalation trial of OMS721 to treat thrombotic microangiopathies (TMAs) including atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura ( TTP).

Omeros said the trial's pre-specified primary endpoint of change from baseline in platelet count was also a primary endpoint in trials of Alexion Pharmaceuticals Inc.'s (NASDAQ:ALXN) Soliris eculizumab to treat aHUS, leading to that drug's U.S. and EU approval in the indication. Neither Omeros' Phase II study nor Alexion's pivotal trials to treat aHUS were placebo-controlled. ...